169 related articles for article (PubMed ID: 27858752)
1. An Antibody to Detect Alanine-Expanded PABPN1: A New Tool to Study Oculopharyngeal Muscular Dystrophy.
Vest KE; Apponi LH; Banerjee A; Pavlath GK; Corbett AH
J Neuromuscul Dis; 2015 Oct; 2(4):439-446. PubMed ID: 27858752
[TBL] [Abstract][Full Text] [Related]
2. Proteomic analysis reveals that wildtype and alanine-expanded nuclear poly(A)-binding protein exhibit differential interactions in skeletal muscle.
Banerjee A; Phillips BL; Deng Q; Seyfried NT; Pavlath GK; Vest KE; Corbett AH
J Biol Chem; 2019 May; 294(18):7360-7376. PubMed ID: 30837270
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial localization of PABPN1 in oculopharyngeal muscular dystrophy.
Doki T; Yamashita S; Wei FY; Hara K; Yamamoto T; Zhang Z; Zhang X; Tawara N; Hino H; Uyama E; Kurashige T; Maruyama H; Tomizawa K; Ando Y
Lab Invest; 2019 Nov; 99(11):1728-1740. PubMed ID: 30894671
[TBL] [Abstract][Full Text] [Related]
4. Functional impact of an oculopharyngeal muscular dystrophy mutation in PABPN1.
García-Castañeda M; Vega AV; Rodríguez R; Montiel-Jaen MG; Cisneros B; Zarain-Herzberg A; Avila G
J Physiol; 2017 Jul; 595(13):4167-4187. PubMed ID: 28303574
[TBL] [Abstract][Full Text] [Related]
5. Study of a Taiwanese family with oculopharyngeal muscular dystrophy.
Kuo HC; Chen CM; Lee-Chen GJ; Hu FJ; Chu CC; Liou CW; Huang CC
J Neurol Sci; 2009 Mar; 278(1-2):21-4. PubMed ID: 19101703
[TBL] [Abstract][Full Text] [Related]
6. PABPN1 loss-of-function causes APA-shift in oculopharyngeal muscular dystrophy.
Shademan M; Mei H; van Engelen B; Ariyurek Y; Kloet S; Raz V
HGG Adv; 2024 Apr; 5(2):100269. PubMed ID: 38213032
[TBL] [Abstract][Full Text] [Related]
7. Cytoplasmic targeting of mutant poly(A)-binding protein nuclear 1 suppresses protein aggregation and toxicity in oculopharyngeal muscular dystrophy.
Abu-Baker A; Laganiere S; Fan X; Laganiere J; Brais B; Rouleau GA
Traffic; 2005 Sep; 6(9):766-79. PubMed ID: 16101680
[TBL] [Abstract][Full Text] [Related]
8. Novel mouse models of oculopharyngeal muscular dystrophy (OPMD) reveal early onset mitochondrial defects and suggest loss of PABPN1 may contribute to pathology.
Vest KE; Phillips BL; Banerjee A; Apponi LH; Dammer EB; Xu W; Zheng D; Yu J; Tian B; Pavlath GK; Corbett AH
Hum Mol Genet; 2017 Sep; 26(17):3235-3252. PubMed ID: 28575395
[TBL] [Abstract][Full Text] [Related]
9. Animal model of oculopharyngeal muscular dystrophy.
Uyama E; Hino H; Araki K; Takeya M; Uchino M; Yamamura K
Acta Myol; 2005 Oct; 24(2):84-8. PubMed ID: 16550922
[TBL] [Abstract][Full Text] [Related]
10. Nuclear entrapment and extracellular depletion of PCOLCE is associated with muscle degeneration in oculopharyngeal muscular dystrophy.
Raz V; Sterrenburg E; Routledge S; Venema A; van der Sluijs BM; Trollet C; Dickson G; van Engelen BG; van der Maarel SM; Antoniou MN
BMC Neurol; 2013 Jul; 13():70. PubMed ID: 23815790
[TBL] [Abstract][Full Text] [Related]
11. Wild-type PABPN1 is anti-apoptotic and reduces toxicity of the oculopharyngeal muscular dystrophy mutation.
Davies JE; Sarkar S; Rubinsztein DC
Hum Mol Genet; 2008 Apr; 17(8):1097-108. PubMed ID: 18178579
[TBL] [Abstract][Full Text] [Related]
12. A Case of Oculopharyngeal Muscular Dystrophy Caused by a Novel PABPN1 c.34G > T (p.Gly12Trp) Point Mutation without Polyalanine Expansion.
Takahashi Y; Morimoto N; Nada T; Morimoto M; Eura N; Minami N; Nishino I
J Neuromuscul Dis; 2023; 10(3):459-463. PubMed ID: 36847015
[TBL] [Abstract][Full Text] [Related]
13. Characterization of
Cruz-Aguilar M; Guerrero-de Ferran C; Tovilla-Canales JL; Nava-Castañeda A; Zenteno JC
J Investig Med; 2017 Mar; 65(3):705-708. PubMed ID: 27980005
[TBL] [Abstract][Full Text] [Related]
14. Oculopharyngeal muscular dystrophy as a paradigm for muscle aging.
Raz Y; Raz V
Front Aging Neurosci; 2014; 6():317. PubMed ID: 25426070
[TBL] [Abstract][Full Text] [Related]
15. Myopathy phenotype in transgenic mice expressing mutated PABPN1 as a model of oculopharyngeal muscular dystrophy.
Hino H; Araki K; Uyama E; Takeya M; Araki M; Yoshinobu K; Miike K; Kawazoe Y; Maeda Y; Uchino M; Yamamura K
Hum Mol Genet; 2004 Jan; 13(2):181-90. PubMed ID: 14645203
[TBL] [Abstract][Full Text] [Related]
16. Nuclear speckles are involved in nuclear aggregation of PABPN1 and in the pathophysiology of oculopharyngeal muscular dystrophy.
Bengoechea R; Tapia O; Casafont I; Berciano J; Lafarga M; Berciano MT
Neurobiol Dis; 2012 Apr; 46(1):118-29. PubMed ID: 22249111
[TBL] [Abstract][Full Text] [Related]
17. Nuclear poly(A) binding protein 1 (PABPN1) and Matrin3 interact in muscle cells and regulate RNA processing.
Banerjee A; Vest KE; Pavlath GK; Corbett AH
Nucleic Acids Res; 2017 Oct; 45(18):10706-10725. PubMed ID: 28977530
[TBL] [Abstract][Full Text] [Related]
18. RNA-Based Therapy Utilizing Oculopharyngeal Muscular Dystrophy Transcript Knockdown and Replacement.
Abu-Baker A; Kharma N; Perreault J; Grant A; Shekarabi M; Maios C; Dona M; Neri C; Dion PA; Parker A; Varin L; Rouleau GA
Mol Ther Nucleic Acids; 2019 Apr; 15():12-25. PubMed ID: 30831428
[TBL] [Abstract][Full Text] [Related]
19. PABPN1 gene therapy for oculopharyngeal muscular dystrophy.
Malerba A; Klein P; Bachtarzi H; Jarmin SA; Cordova G; Ferry A; Strings V; Espinoza MP; Mamchaoui K; Blumen SC; St Guily JL; Mouly V; Graham M; Butler-Browne G; Suhy DA; Trollet C; Dickson G
Nat Commun; 2017 Mar; 8():14848. PubMed ID: 28361972
[TBL] [Abstract][Full Text] [Related]
20. Cystamine suppresses polyalanine toxicity in a mouse model of oculopharyngeal muscular dystrophy.
Davies JE; Rose C; Sarkar S; Rubinsztein DC
Sci Transl Med; 2010 Jun; 2(34):34ra40. PubMed ID: 20519718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
